Monoclonal Antibodies Found Effective Against BA.x Variants
Taiwan-based AcadeMab Biomedical Inc. recently announced it developed several potent and broad-spectrum COVID-19 therapeutic antibodies for the SARS-CoV-2 virus Omicron and Delta variants.
On May 26, 2022, AcadeMab confirmed its monoclonal antibodies for COVID-19 patients using single B cell technology, showing the best neutralization ability (IC50 = 11.4 and 4.3 ng/ml) in both Omicron variants BA.1 and BA.2 respectively.
"We are excited to announce that our research and development efforts have paid off at a fast pace with our single B cell technology that's shown neutralizing efficacy against the world's most common and deadly Omicron variant," shared Juz-Hsiang Chiu, M.D., AcadeMab CEO, in a press release.
This type of treatment is beneficial to those who have a documented history of severe adverse reactions to existing COVID-19 vaccines or their components and are unable to be vaccinated.
Additional antibody development news is posted at CoronavirusToday.com/Antibody.
Note: This information was manually curated for mobile readers.